# To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT

> **NCT07280494** · PHASE1 · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 18 (estimated)

## Conditions studied

- CD7+ T-ALL/LBL

## Interventions

- **DRUG:** CAR-T Therapy

## Key facts

- **NCT ID:** NCT07280494
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-18
- **Primary completion:** 2026-08-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07280494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07280494, "To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07280494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*